## *Vibrio vulnificus* VvhA induces autophagy-related cell death through the lipid raft-dependent c-Src/NOX signaling pathway

Eun Ju Song<sup>1, +</sup>, Sei-Jung Lee<sup>1, +</sup>, Hyeon Su Lim<sup>1</sup>, Jun Sung Kim<sup>1</sup>, Kyung Ku Jang<sup>2</sup>, Sang Ho Choi<sup>2</sup>, and Ho Jae Han<sup>1,\*</sup>

## **Supplementary Materials and Methods**

**Purification of the recombinant haemolysin VvhA.** To find the molecular role of VvhA in Caco-2 cells, we prepared a recombinant protein of VvhA (rVvhA) following the method of Lee et al.<sup>1</sup>. Briefly, the coding region of *vvhA* was amplified and then cloned into a His6-tag expression vector, pET29a(+) (Novagen, Madison, WI, USA), resulting in pKS1201 (Supplementary Table S1). *E. coli* BL21 (DE3) carrying the pKS1201 was grown in LB-ampicillin media at 37 °C until reaching an  $A_{600}$  between 0.5 and 0.6. For inducing the protein expression, the temperature was lowered to 30 °C and the culture treated with 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside for 6 h. The cells were harvested and prepared for isolating the soluble fraction. Cell lysate containing His<sub>6</sub>-tagged VvhBA protein was mixed with 1 ml of Ni-NTA agarose (Qiagen, Valencia, CA) for 1 h at 4 °C and the mixture was loaded on Bio-Spin Chromatography Columns (Bio-Rad Laboratories, Hercules, CA, USA). The resin was washed with buffer A, and bound VvhBA protein was eluted with buffer A containing 300 mM imidazole. After purification, the homogeneity of VvhBA was assessed by 12 % SDS-PAGE and Coomassie Blue staining. Purified proteins containing rVvhA was dialyzed against 20 mM Tris-Cl, pH 8.0, concentrated to 0.3 mg/mL using Slide-A-Lyzer Dialysis Cassettes (Thermo Scientific, Hudson, NH, USA), and stored at -80 °C until use.

Bacterial strains, plasmids, and culture media. The strains and plasmid used in the present study

are listed in Supplementary Table S1. All *V. vulnificus* strains (M06-24/O WT and M06-24/O *vvhA*) are isogenic and naturally resistant to polymyxin B. *V. vulnificus* strains were cultured in LB medium supplemented with 2.0 % (w/v) NaCl (LBS) at 30 °C. All media components were obtained from Difco Laboratories (Detroit, MI, USA). The bacterial strains were grown to mid-log phase ( $A_{600} = 0.500$ ) corresponding 2 × 10<sup>8</sup> CFU/mL and centrifuged at 6000 × g for 5 min. The pellet was washed with PBS and prepared to desired colony-forming unit (CFU)/mL based on the  $A_{600}$  determined using a UV–VIS spectrophotometer (UV-1800, Shimadzu, Japan).

**Complementation of the** *vvhA* **mutant**. To complement the *vvhA* mutation, an open reading frame (ORF) of *vvhA* was amplified from the genomic DNA of *Vibrio vulnificus* MO6-24/O by PCR with the primer pair VVHA001F and VVHA001R (Supplementary Table S2) and then digested with BamHI. The amplified *vvhA* ORF was subcloned into the broad-host-range vector pRK415 linearized with the same enzyme (Supplementary Table S1) to result in pKK1449<sup>2</sup>. *Escherichia coli* S17-1  $\lambda$  *pir*, *tra* strain containing pKK1449 was used as a conjugal donor to *vvhA* mutant<sup>3</sup>. The plasmid pKK1449 was delivered into the *vvhA* mutant by conjugation as described previously<sup>4</sup>.

## **References for Supplementary**

- Lee, S. et al. *Vibrio vulnificus* VvhA induces NF-κB-dependent mitochondrial cell death via lipid raft-mediated ROS production in intestinal epithelial cells. Cell death & disease 6, 1655 (2015).
- Keen, N., Tamaki, S., Kobayashi, D. & Trollinger, D. Improved broad-host-range plasmids for DNA cloning in gram-negative bacteria. Gene 70, 191-197 (1988).
- 3. Simon, R., Priefer, U. & Pühler, A. A broad host range mobilization system for invivo geneticengineering-transposon mutagenesis in gram-negative bacteria. Bio-technology 1 (1983).
- 4. Park, J. H. et al. Correction: The cabABC Operon Essential for Biofilm and Rugose Colony Development in *Vibrio vulnificus*. PLoS pathogens 11, e1005252-e1005252 (2015).

| <b>Relevant characteristics</b> <sup>a</sup>  | Reference or source   |
|---|---|
|   |   |
|   |   |
| Clinical isolate; virulent; WT  | Laboratory collection   |
|   |   |
| $F ompT hsdS_B (r_B m_B) gal dcm (DE3)$   | Laboratory collection   |
| $\lambda$ - <i>pir</i> lysogen; <i>thi pro hsdR hsdM</i> <sup>+</sup> <i>recA</i> RP4-2 Tc::Mu-<br>Km::Tn7;Tp <sup>r</sup> Sm <sup>r</sup> ; host for $\pi$ -requiring plasmids; conjugal donor | Simon <i>et al.</i> , 1983 <sup>3</sup>   |
|   |   |
| His <sub>6</sub> tag fusion expression vector; Km <sup>r</sup>  | Novagen   |
| pET29a(+) with VvhBA; Km <sup>r</sup>   | Lee <i>et al.</i> , 2015 <sup>1</sup>   |
| IncP <i>ori</i> ; broad-host-range vector, <i>oriT</i> of RP4; Tc <sup>r</sup>  | Keen <i>et al.</i> , 1988 <sup>2</sup>  |
| pRK415 with <i>vvhA</i> ; Tc <sup>r</sup>   | This study  |
|   | Clinical isolate; virulent; WT<br>$F^{r}$ ompT hsdS <sub>B</sub> (r <sub>B</sub> 'm <sub>B</sub> ') gal dcm (DE3)<br>$\lambda$ -pir lysogen; thi pro hsdR hsdM <sup>+</sup> recA RP4-2 Tc::Mu-<br>Km::Tn7;Tp <sup>r</sup> Sm <sup>r</sup> ; host for $\pi$ -requiring plasmids;<br>conjugal donor<br>His <sub>6</sub> tag fusion expression vector; Km <sup>r</sup><br>pET29a(+) with VvhBA; Km <sup>r</sup><br>IncP ori; broad-host-range vector, oriT of RP4; Tc <sup>r</sup> |

Supplementary Table 1. Plasmids and bacterial strains used in this study

<sup>a</sup> Tp<sup>r</sup>, trimethoprim resistant; Sm<sup>r</sup>, streptomycin resistant; Tc<sup>r</sup>, tetracycline resistant

| Genes      | Forward primer/reverse primer   |
|------------|---|
| ULK1       | 5'-CAGAACTACCAGCGCATTGA-3'<br>5'-TCCACCCAGAGACATCTTCC-3'                    |
| ULK2       | 5'-CTCCTCAGGTTCTCCAGTGC-3'<br>5'-TTGGTGGGAGAAGTTCCAAG-3'                    |
| ATG14      | 5'-TCACCATCCAGGAACTCACA-3'<br>5'-TTCAGTCTTCGGCTGAGGTT-3'                    |
| VPS34      | 5'-ATGTGTATGGTCCCGGAAAA-3'<br>5'-TGTCGATGAGCTTTGGTGAG-3'                    |
| BECLIN-1   | 5'-GCCCTTTGAAGTACGAGCAG-3'<br>5'-GAGATCATCCCACCTGCACT-3'                    |
| ATG5       | 5'-CGGGAACACCAAGTTTCACT-3'<br>5'-TCTGGGGAGACATCCGTAAG-3'                    |
| ATG12      | 5'-TGGGATTGCAAAATGACAGA-3'<br>5'-TTCCCCATCTTCAGGATCAA-3'                    |
| ATG16L1    | 5'-GTCTTCGATGCACATGATGG-3'<br>5'-GATTCGGCTTGCAAAATCAT-3'                    |
| LC3B       | 5'-AGCAGCATCCAACCAAAATC-3'<br>5'-CTGTGTCCGTTCACCAACAG-3'                    |
| P62/SQSTM1 | 5'-CACCTGTCTGAGGGCTTCTC-3'<br>5'-CACACTCTCCCCAACGTTCT-3'                    |
| RAB7       | 5'-CTGACCAAGGAGGTGATGGT-3'<br>5'-CTGGCCTGGATGAGAAACTC-3'                    |
| FYCO1      | 5'-GGAGCTAGGAGCAGCAGAGA-3'<br>5'-CGCATCACTGGGAATAGGTT-3'                    |
| LAMP1      | 5'-CTTCAGCAGGGGAGAGACAC-3'<br>5'-TGTTGGGGTTGATGTTGAGA-3'                    |
| LAMP2      | 5'-GGTTAATGGCTCCGTTTTCA-3'<br>5'-ATGGGCACAAGGAAGTTGTC-3'                    |
| β-Actin    | 5'-AACCGCGAGAAGATGACCCAGATCATGTTT-3'<br>5'-AGCAGCCGTGGCCATCTTTGCTCGAAGTC-3' |


Supplementary Table 2. Sequences of primer pairs used in this study.

Supplementary Table 3. Oligonucleotides used in this study

| Amplification of the |
|----------------------|
| vvhA ORF             |
|                      |


<sup>a</sup> The oligonucleotides were designed using the *V. vulnificus* MO6-24/O genomic sequence (GenBank<sup>TM</sup> accession number CP002469 and CP002470, www.ncbi.nlm.nih.gov).

<sup>b</sup> Regions of oligonucleotides not complementary to the corresponding genes are underlined.



## Supplementary Figure 1. Effect of rVvhA on ER stress.

(a) Time responses of rVvhA in the expression of CHOP were confirmed by western blotting. n = 3. (b) Cells were transfected for 36 h with *eIF2a* or *non-targeting* (*nt*) siRNA using TurboFect Transfection Reagent prior to rVvhA exposure for 6 h. CHOP expression was analyzed by using Western blot. n = 3.



Supplementary Figure 2. Effect of siRNA on target protein. Cells were transfected for 36 h with *eIF2a* or *non-targeting* (*nt*) siRNA using TurboFect Transfection Reagent. Protein expressions were analyzed by using Western blot. The knockdown efficacies of eIF2a was 65%. Error bars represent the means  $\pm$  S.E. \**P* < 0.05 vs *nt* siRNA